"10.1371_journal.pone.0058438","plos one","2013-03-05T00:00:00Z","Christian Wolf; Jagdev Sidhu; Christian Otoul; Dexter L Morris; Jennifer Cnops; Jorg Taubel; Barbara Bennett","Clinical Development, Lycalis s.p.r.l., Brussels, Belgium; Clinical Pharmacology/Early Development, CSL Ltd., Melbourne, Australia; Exploratory Statistics, UCB Pharma, Brabant, Belgium; Drug Development, UCB Biosciences Inc., Raleigh, North Carolina, United States of America; Department of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; Richmond Pharmacology, London, United Kingdom; BABennett Consulting, Marietta, Georgia, United States of America","Conceived and designed the experiments: CW JS CO JT. Performed the experiments: JT. Analyzed the data: CW JS CO DLM JC JT BB. Wrote the paper: CW JS CO DLM JC JT BB.","This study was funded by UCB Pharma and Biogen Idec, which were jointly developing CDP323 as a potential treatment for multiple sclerosis. Dr. Morris has been an employee of and holds stock in GlaxoSmithKline and is currently employed by and has received stock options from UCB Biosciences Inc. Among my coauthors, Dr. Wolf was a salaried employee of UCB Pharma S.A. during the time the study was conducted and has been a consultant for Novartis and Synthon. Dr. Sidhu was a salaried employee of and received stock in UCB Pharma during the time the study was conducted. Dr. Otoul is an employee of UCB Pharma. Dr. Taubel is employed by Richmond Pharmacology, which received financial remuneration for their clinical involvement in this study. Dr. Bennett was a salaried employee of UCB Biosciences Inc. during the time the study was conducted and is now an independent consultant. Dr. Cnops reports no conflicts of interest. This does not alter the authors adherence to all of the PLOS ONE policies on sharing data and materials.","2013","03","Christian Wolf","CW",7,TRUE,4,1,7,7,TRUE,TRUE,FALSE,0,NA,FALSE
